Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Pateinakis, A. Pyrpasopoulou (2014)
CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?BioMed Research International, 2014
N. Kothary, Ida-Lina Diak, A. Brinker, Shewit Bezabeh, M. Avigan, G. Pan (2011)
Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.Journal of the American Academy of Dermatology, 65 3
J. Keane, S. Gershon, R. Wise, E. Mirabile-Levens, J. Kasznica, W. Schwieterman, J. Siegel, M. Braun (2001)
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.The New England journal of medicine, 345 15
S. Arend, E. Leyten, W. Franken, E. Huisman, J. Dissel (2007)
A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 11
N. Schwab, J. Ulzheimer, R. Fox, T. Schneider-Hohendorf, T. Schneider-Hohendorf, B. Kieseier, C. Monoranu, S. Staugaitis, W. Welch, S. Jilek, R. Pasquier, W. Brück, K. Toyka, R. Ransohoff, H. Wiendl, H. Wiendl (2012)
Fatal PML associated with efalizumab therapyNeurology, 78
K. Carson, D. Focosi, E. Major, M. Petrini, E. Richey, D. West, C. Bennett (2009)
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.The Lancet. Oncology, 10 8
P. Ingram, R. Howman, M. Leahy, J. Dyer (2007)
Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 44 12
Yanping Hu, M. Turner, J. Shields, M. Gale, E. Hutto, B. Roberts, W. Siders, J. Kaplan (2009)
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse modelImmunology, 128
I. Metz, E. Radue, A. Oterino, T. Kümpfel, H. Wiendl, S. Schippling, J. Kuhle, M. Sahraian, F. Gray, V. Jakl, Darius Häusler, W. Brück (2011)
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathyActa Neuropathologica, 123
J. Berger (2014)
Progressive multifocal leukoencephalopathy.Handbook of clinical neurology, 123
R. Wallis (2008)
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.The Lancet. Infectious diseases, 8 10
Nina Singh (2008)
Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycosesEuropean Journal of Clinical Microbiology & Infectious Diseases, 27
C. Warnke, Anne Mausberg, M. Stettner, T. Dehmel, Lina Nekrich, Gerd Horste, H. Hartung, A. Fogdell-Hahn, O. Adams, B. Kieseier (2013)
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosisNeurology, 81
N. Wysham, D. Sullivan, G. Allada (2013)
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.Chest, 143 5
Nina Singh, O. Lortholary, B. Alexander, K. Gupta, G. John, K. Pursell, P. Muñoz, G. Klintmalm, V. Stosor, R. Busto, A. Limaye, J. Somani, Marshall Lyon, S. Houston, A. House, T. Pruett, S. Orloff, A. Humar, Lorraine Dowdy, J. Garcia-Diaz, A. Kalil, R. Fisher, S. Husain (2005)
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40 12
C. Tan, I. Koralnik (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 9
B. Kleinschmidt-DeMasters, Augusto Miravalle, J. Schowinsky, J. Corboy, T. Vollmer (2012)
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With NatalizumabJournal of Neuropathology & Experimental Neurology, 71
B. Saunders, Stephen Tran, S. Ruuls, J. Sedgwick, H. Briscoe, W. Britton (2005)
Transmembrane TNF Is Sufficient to Initiate Cell Migration and Granuloma Formation and Provide Acute, but Not Long-Term, Control of Mycobacterium tuberculosis Infection1The Journal of Immunology, 174
A. Bean, D. Roach, H. Briscoe, H. Briscoe, H. Körner, J. Sedgwick, W. Britton, W. Britton (1999)
Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.Journal of immunology, 162 6
R. Wathes, S. Moule, D. Milojkovic (2013)
Progressive multifocal leukoencephalopathy associated with ruxolitinib.The New England journal of medicine, 369 2
V. Cheng, P. Ho, R. Lee, K. Chan, Patrick Woo, S. Lau, K. Yuen (2002)
Clinical Spectrum of Paradoxical Deterioration During Antituberculosis Therapy in Non-HIV-Infected PatientsEuropean Journal of Clinical Microbiology and Infectious Diseases, 21
A. Minagar (2012)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohortYearbook of Neurology and Neurosurgery, 2012
T. Blackmore, Lauren Manning, W. Taylor, R. Wallis (2008)
Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 47 10
T. Walker (2013)
FDA rejects MS drugFormulary
H. Algood, P. Lin, J. Flynn (2005)
Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 Suppl 3
J. Canaani, S. Amit, J. Ben-Ezra, M. Pour, N. Sarid, H. Lerman, C. Perry, A. Polliack, E. Naparstek, Y. Herishanu (2013)
Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 11
Stefanie Dahlhaus, R. Hoepner, A. Chan, I. Kleiter, O. Adams, C. Lukas, K. Hellwig, R. Gold (2013)
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patientsJournal of Neurology, Neurosurgery, and Psychiatry, 84
M. Lima (2013)
Progressive multifocal leukoencephalopathy: new concepts.Arquivos de neuro-psiquiatria, 71 9B
S Gheuens (2012)
10.1212/WNL.0b013e318253d61eNeurology, 78
C. Rivoisy, L. Amrouche, G. Carcelain, D. Séréni, A. Bourgarit (2011)
Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome.Joint, bone, spine : revue du rhumatisme, 78 3
B. Estruch (2013)
Safety profile and practical considerations of monoclonal antibody treatmentNeurologia, 28
J Keane (2001)
10.1056/NEJMoa011110N Engl J Med, 345
B. Golas, D. Magge, A. Zureikat, H. Zeh, H. Alexander, S. Libutti, R. Royal, M. Hughes, M. Holtzman, K. Turaga, S. Pappas, T. Gamblin, D. Bartlett, J. Pingpank (2013)
Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver.Journal of Clinical Oncology, 31
M. Wattjes, L. Verhoeff, Willemijn Zentjens, J. Killestein, E. Munster, F. Barkhof, J. Eijk (2013)
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?Journal of Neurology, Neurosurgery & Psychiatry, 84
R. Wallis (2005)
Reconsidering adjuvant immunotherapy for tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 2
Hsin-Yun Sun, Nina Singh (2009)
Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patientsCurrent Opinion in Infectious Diseases, 22
V. Mohan, C. Scanga, Keming Yu, H. Scott, Kathryn Tanaka, Enders Tsang, Ming-Chih Tsai, J. Flynn, J. Chan (2001)
Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting PathologyInfection and Immunity, 69
D. Roach, A. Bean, C. Demangel, M. France, H. Briscoe, W. Britton (2002)
TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1The Journal of Immunology, 168
P. Giacomini, Ayal Rozenberg, I. Metz, David Araújo, N. Arbour, A. Bar-Or (2014)
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.The New England journal of medicine, 370 5
M. Cossburn, A. Pace, Judson Jones, R. Ali, G. Ingram, K. Baker, C. Hirst, J. Zajicek, N. Scolding, M. Boggild, T. Pickersgill, Y. Ben-Shlomo, A. Coles, N. Robertson (2011)
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohortNeurology, 77
S. Melboucy-Belkhir, Gabriella Flexor, J. Stirnemann, A. Morin, L. Boukari, C. Polliand, P. Cruaud, O. Fain (2010)
Prolonged paradoxical response to anti-tuberculous treatment after infliximab.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 14 Suppl 3
J. Cadena, G. Thompson, Tony Ho, E. Medina, D. Hughes, T. Patterson (2009)
Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia.Diagnostic microbiology and infectious disease, 64 3
B. Estruch (2013)
Perfil de seguridad y aspectos prácticos a tener en cuenta en la administración de anticuerpos monoclonalesNeurologia, 28
Y. Yoon, J. Kim, J. Sohn, M. Kim, J. Koo, J. Choi, D. Park (2009)
Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case reportJournal of Medical Case Reports, 3
D. Barber, B. Andrade, I. Sereti, A. Sher (2012)
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had noneNature Reviews Microbiology, 10
M. Takao (2013)
[Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].Brain and nerve = Shinkei kenkyu no shinpo, 65 11
Jianming Zhang, Priscilla Yang, N. Gray (2009)
Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 9
A. Weetman (2009)
Immune reconstitution syndrome and the thyroid.Best practice & research. Clinical endocrinology & metabolism, 23 6
S. Shelburne, R. Hamill, M. Rodriguez‐Barradas, S. Greenberg, R. Atmar, D. Musher, J. Gathe, F. Visnegarwala, B. Trautner (2002)
Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral TherapyMedicine, 81
A. Schröder, De-hyung Lee, K. Hellwig, C. Lukas, R. Linker, R. Gold (2010)
Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.Archives of neurology, 67 11
R. Wallis (2009)
Infectious complications of tumor necrosis factor blockadeCurrent Opinion in Infectious Diseases, 22
J. O’Shea, S. Holland, L. Staudt (2013)
JAKs and STATs in immunity, immunodeficiency, and cancer.The New England journal of medicine, 368 2
T. Johnson, A. Nath (2011)
Immune reconstitution inflammatory syndrome and the central nervous system.Current opinion in neurology, 24 3
M. Blinkenberg, F. Sellebjerg, A. Leffers, C. Madsen, P. Sørensen (2013)
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumabMultiple Sclerosis Journal, 19
C. Vidal, Serena Fernández, J. Lacasa, M. Salavert, R. Vidal, M. Carballeira, J. Garau (2005)
Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 40 5
J. Flynn, M. Goldstein, J. Chan, Karla Triebold, K. Pfeffer, C. Lowenstein, Robert Schrelber, T. Mak, B. Bloom (1995)
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.Immunity, 2 6
C. Hage, S. Bowyer, S. Tarvin, D. Helper, M. Kleiman, L. Wheat (2010)
Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 1
R. Fox (2011)
Advances in the management of PML: Focus on natalizumabCleveland Clinic Journal of Medicine, 78
Steffen Hess, T. Hospach, R. Nossal, G. Dannecker, K. Magdorf, F. Uhlemann (2011)
Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescentEuropean Journal of Pediatrics, 170
F. Zaheer, J. Berger (2012)
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsTherapeutic Advances in Drug Safety, 3
F. Veerdonk, B. Lauwerys, R. Marijnissen, K. Timmermans, F. Padova, M. Koenders, I. Gutierrez-Roelens, P. Durez, M. Netea, J. Meer, W. Berg, L. Joosten (2011)
The anti-CD20 antibody rituximab reduces the Th17 cell response.Arthritis and rheumatism, 63 6
M. Wattjes, N. Richert, J. Killestein, M. Vos, E. Sánchez, P. Snaebjornsson, D. Cadavid, F. Barkhof (2013)
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyMultiple Sclerosis Journal, 19
(2010)
Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system
K. Carson, A. Evens, E. Richey, T. Habermann, D. Focosi, J. Seymour, J. Laubach, Susie Bawn, L. Gordon, J. Winter, R. Furman, J. Vose, A. Zelenetz, R. Mamtani, D. Raisch, Gary Dorshimer, S. Rosen, K. Muro, N. Gottardi-Littell, R. Talley, O. Sartor, D. Green, E. Major, C. Bennett (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.Blood, 113 20
J. Singh, D. Furst, A. Bharat, J. Curtis, A. Kavanaugh, J. Kremer, L. Moreland, J. O'dell, K. Winthrop, T. Beukelman, S. Bridges, W. Chatham, H. Paulus, M. Suarez‐Almazor, C. Bombardier, M. Dougados, D. Khanna, Charles King, Amye Leong, E. Matteson, J. Schousboe, Eileen Moynihan, K. Kolba, Archana Jain, E. Volkmann, Harsh Agrawal, S. Bae, A. Mudano, N. Patkar, K. Saag (2012)
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 64
R. Breen, C. Smith, H. Bettinson, S. Dart, B. Bannister, Margaret Johnson, M. Lipman (2004)
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infectionThorax, 59
G. Köhler, C. Milstein (1975)
Continuous cultures of fused cells secreting antibody of predefined specificityNature, 256
C. Antoniol, S. Jilek, M. Schluep, Noëlle Mercier, Mathieu Canales, G. Goff, Claudia Campiche, G. Pantaleo, R. Pasquier (2012)
Impairment of JCV-specific T-cell response by corticotherapyNeurology, 79
N. Schwab, K. Höhn, T. Schneider-Hohendorf, I. Metz, Max-Philipp Stenner, S. Jilek, R. Pasquier, R. Gold, S. Meuth, R. Ransohoff, W. Brück, H. Wiendl (2012)
Immunological and clinical consequences of treating a patient with natalizumabMultiple Sclerosis Journal, 18
A. Tefferi, A. Pardanani (2011)
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.Mayo Clinic proceedings, 86 12
Thomas Benkert, L. Dietz, E. Hartmann, E. Leich, A. Rosenwald, E. Serfling, M. Buttmann, F. Berberich-Siebelt (2012)
Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple SclerosisPLoS ONE, 7
S. Marousi, M. Travasarou, C. Karageorgiou (2012)
Simultaneous Pml-Iris After Discontinuation of Natalizumab in A Patient With MSNeurology, 79
M. Gardam, E. Keystone, R. Menzies, S. Manners, E. Skamene, R. Long, D. Vinh (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.The Lancet. Infectious diseases, 3 3
C. Cervera (2012)
Natalizumab-associated progressive multifocal leukoencephalopathy.The New England Journal of Medicine, 367
A. Safdar, A. Brown, D. Kraus, M. Malkin (2000)
Paradoxical reaction syndrome complicating aural infection due to Mycobacterium tuberculosis during therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 30 3
R. Broady, M. Levings (2008)
Graft-versus-host disease: suppression by statinsNature Medicine, 14
D. Clifford (2015)
Progressive multifocal leukoencephalopathy therapyJournal of NeuroVirology, 21
I. Tan, J. Mcarthur, D. Clifford, E. Major, A. Nath (2011)
Immune reconstitution inflammatory syndrome in natalizumab-associated PMLNeurology, 77
Y. Belkaid (2007)
Regulatory T cells and infection: a dangerous necessityNature Reviews Immunology, 7
DB Clifford (2010)
10.1016/S1474-4422(10)70028-4Lancet Neurol, 9
R. Wallis, C. Vuuren, S. Potgieter (2009)
Adalimumab treatment of life-threatening tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48 10
R. Belknap, R. Reves, W. Burman (2005)
Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 9 9
A. Ostojic, R. Vrhovac, S. Verstovsek (2012)
Ruxolitinib for the treatment of myelofibrosis: its clinical potentialTherapeutics and Clinical Risk Management, 8
Andrew Fine, A. Sorbello, C. Kortepeter, Linda Scarazzini (2014)
Progressive multifocal leukoencephalopathy after natalizumab discontinuationAnnals of Neurology, 75
R. Wallis, M. Broder, J. Wong, M. Hanson, D. Beenhouwer (2004)
Granulomatous infectious diseases associated with tumor necrosis factor antagonists.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38 9
M. Lionakis, D. Kontoyiannis (2003)
Glucocorticoids and invasive fungal infectionsThe Lancet, 362
J Berger (2010)
10.2165/11537510-000000000-00000Drug Saf, 33
C. Debeuckelaere, P. Munter, P. Bleyenbergh, W. Wever, G. Assche, P. Rutgeerts, S. Vermeire (2014)
Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening.Journal of Crohn's & colitis, 8 6
The use of biologics in the treatment of autoimmune disease, cancer, and other immune conditions has revolutionized medical care in these areas. However, there are drawbacks to the use of these medications including increased susceptibility to opportunistic infections. One unforeseen risk once opportunistic infection has occurred with biologic use is the onset of immune reconstitution inflammatory syndrome (IRIS) upon drug withdrawal. Although originally described in human immunodeficiency virus (HIV) patients receiving highly active antiretroviral therapy, it has become clear that IRIS may occur when recovery of immune function follows opportunistic infection in the setting of previous immune compromise/suppression. In this review, we draw attention to this potential pitfall on the use of biologic drugs.
Current Allergy and Asthma Reports – Springer Journals
Published: Feb 1, 2015
Keywords: Immune reconstitution inflammatory syndrome; Monoclonal antibodies; JAK inhibitors; Biologics; Autoimmunity; Progressive multifocal leukoencephalopathy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.